Tiny dialysis study hopes magnesium tweak calms blood cells

NCT ID NCT07206524

Recruiting now Knowledge-focused Sponsor: Universitair Ziekenhuis Brussel Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether adjusting magnesium levels in dialysis fluid can reduce harmful blood cell activation during treatment. Fifteen adults with kidney failure will try three different dialysis fluid recipes over six weeks. Researchers will measure blood cell counts and inflammation markers, but this is an early exploratory study, not a proven therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dialysate with varying magnesium concentrations (0.5, 0.75, 1.0 mmol/L) and acid type (acetic vs. citric)
What this could lead to: If successful, this could point toward a safer dialysis recipe that reduces inflammation and clotting risks for kidney patients.
What could go wrong: This is a very small pilot study (15 people) looking at lab markers, not patient outcomes. It may not lead to any practical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE (ESRD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease dialysis disequilibrium syndrome end stage renal failure Thromboinflammation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

END STAGE RENAL DISEASE (ESRD) HEMODIALYSIS HEMODIALYSIS COMPLICATION THROMBOINFLAMMATION

Contacts and locations

Show contact details

Locations

Universitair Ziekenhuis Brussel
RECRUITING

Brussels, 1090, Belgium

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.